United Therapeutics (UTHR) saw its stock price plummet by 5.06% in intraday trading on Wednesday following the release of its second-quarter 2025 financial results. The biopharmaceutical company's earnings and revenue fell short of Wall Street expectations, disappointing investors and triggering a sell-off.

The company reported earnings per share (EPS) of $6.41, missing the FactSet consensus estimate of $6.94. While this represents an increase from $5.85 in the same quarter last year, it failed to meet market expectations. Revenue for the quarter came in at $798.6 million, up 11.7% year-over-year but falling short of the analyst consensus of $804.3 million.

Despite reporting record total revenue and highlighting strong performance in key products like Tyvaso DPI, which saw 22% growth over Q2 2024, investors seemed to focus on the earnings miss. The company's announcement of a new $1 billion share repurchase program, expiring in March 2026, did little to offset the negative sentiment. As United Therapeutics continues to invest in its pipeline, including ongoing Phase 3 studies for Nebulized Tyvaso and ralinepag, investors will be closely watching for updates on these potential growth drivers in the coming quarters.